Early posttransplant lymphoproliferative disease

Beverly P. Nelson, Kristy L. Wolniak, Andrew Evens, Anjen Chenn, John Maddalozzo, Maria Proytcheva

Research output: Contribution to journalArticlepeer-review

36 Scopus citations


Early posttransplant lymphoproliferative disorders (EPTLDs) represent the first changes in posttransplant lymphoproliferative disorders (PTLDs) morphologic spectrum. EPTLD data are available mostly from case reports and series that include other types of PTLD. Fifteen EPTLDs were reviewed retrospectively. Clinical data, histopathology, clonality, and Epstein-Barr virus (EBV) status were correlated with staining intensity to an antibody for phosphorylated S6 (pS6) ribosomal protein, a downstream effector of mammalian target of rapamycin (mTOR). Median time from transplantation to EPTLD was 50 months (range, 7-135 mo). EPTLDs involved tonsil and/or adenoids (n = 11) and lymph nodes (n = 4), all of which were nonclonal and EBV-encoded RNA-positive. Most (n = 11) were plasmacytic hyperplasia and florid follicular hyperplasia (n = 4). All regressed with reduced immunosuppression, and had increased pS6 staining compared with normal tonsil (P = .002, F test). EPTLDs developed later than previously reported, involved mostly tonsils/adenoids, were EBV-encoded RNA (EBER) positive, showed increased pS6, and had excellent clinical outcome with reduction of immunosuppression.

Original languageEnglish (US)
Pages (from-to)568-578
Number of pages11
JournalAmerican journal of clinical pathology
Issue number4
StatePublished - Oct 2012

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine


  • EBV
  • Early posttransplant lymphoproliferative disorder
  • Epstein-Barr virus
  • mTOR signaling pathway


Dive into the research topics of 'Early posttransplant lymphoproliferative disease'. Together they form a unique fingerprint.

Cite this